These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1230 related articles for article (PubMed ID: 27339099)

  • 1. Dengue virus sero-cross-reactivity drives antibody-dependent enhancement of infection with zika virus.
    Dejnirattisai W; Supasa P; Wongwiwat W; Rouvinski A; Barba-Spaeth G; Duangchinda T; Sakuntabhai A; Cao-Lormeau VM; Malasit P; Rey FA; Mongkolsapaya J; Screaton GR
    Nat Immunol; 2016 Sep; 17(9):1102-8. PubMed ID: 27339099
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Humoral cross-reactivity between Zika and dengue viruses: implications for protection and pathology.
    Priyamvada L; Hudson W; Ahmed R; Wrammert J
    Emerg Microbes Infect; 2017 May; 6(5):e33. PubMed ID: 28487557
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dengue Virus Envelope Dimer Epitope Monoclonal Antibodies Isolated from Dengue Patients Are Protective against Zika Virus.
    Swanstrom JA; Plante JA; Plante KS; Young EF; McGowan E; Gallichotte EN; Widman DG; Heise MT; de Silva AM; Baric RS
    mBio; 2016 Jul; 7(4):. PubMed ID: 27435464
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cross-reactive dengue virus-derived monoclonal antibodies to Zika virus envelope protein: Panacea or Pandora's box?
    Gunawardana SA; Shaw RH
    BMC Infect Dis; 2018 Dec; 18(1):641. PubMed ID: 30526531
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A protective Zika virus E-dimer-based subunit vaccine engineered to abrogate antibody-dependent enhancement of dengue infection.
    Slon-Campos JL; Dejnirattisai W; Jagger BW; López-Camacho C; Wongwiwat W; Durnell LA; Winkler ES; Chen RE; Reyes-Sandoval A; Rey FA; Diamond MS; Mongkolsapaya J; Screaton GR
    Nat Immunol; 2019 Oct; 20(10):1291-1298. PubMed ID: 31477918
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Modulation of Dengue/Zika Virus Pathogenicity by Antibody-Dependent Enhancement and Strategies to Protect Against Enhancement in Zika Virus Infection.
    Khandia R; Munjal A; Dhama K; Karthik K; Tiwari R; Malik YS; Singh RK; Chaicumpa W
    Front Immunol; 2018; 9():597. PubMed ID: 29740424
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of Anti-Premembrane Antibody as a Serocomplex-Specific Marker To Discriminate Zika, Dengue, and West Nile Virus Infections.
    Hsieh SC; Tsai WY; Tsai JJ; Stone M; Simmons G; Busch MP; Lanteri M; Stramer SL; Balmaseda A; Harris E; Wang WK
    J Virol; 2021 Sep; 95(19):e0061921. PubMed ID: 34232731
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Longitudinal Analysis of Antibody Cross-neutralization Following Zika Virus and Dengue Virus Infection in Asia and the Americas.
    Montoya M; Collins M; Dejnirattisai W; Katzelnick LC; Puerta-Guardo H; Jadi R; Schildhauer S; Supasa P; Vasanawathana S; Malasit P; Mongkolsapaya J; de Silva AD; Tissera H; Balmaseda A; Screaton G; de Silva AM; Harris E
    J Infect Dis; 2018 Jul; 218(4):536-545. PubMed ID: 29618091
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cross-Reaction, Enhancement, and Neutralization Activity of Dengue Virus Antibodies against Zika Virus: A Study in the Mexican Population.
    Montecillo-Aguado MR; Montes-Gómez AE; García-Cordero J; Corzo-Gómez J; Vivanco-Cid H; Mellado-Sánchez G; Muñoz-Medina JE; Gutiérrez-Castañeda B; Santos-Argumedo L; González-Bonilla C; Cedillo-Barrón L
    J Immunol Res; 2019; 2019():7239347. PubMed ID: 31565661
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Human antibody response to Zika targets type-specific quaternary structure epitopes.
    Collins MH; Tu HA; Gimblet-Ochieng C; Liou GA; Jadi RS; Metz SW; Thomas A; McElvany BD; Davidson E; Doranz BJ; Reyes Y; Bowman NM; Becker-Dreps S; Bucardo F; Lazear HM; Diehl SA; de Silva AM
    JCI Insight; 2019 Apr; 4(8):. PubMed ID: 30996133
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Potent Zika and dengue cross-neutralizing antibodies induced by Zika vaccination in a dengue-experienced donor.
    Dussupt V; Sankhala RS; Gromowski GD; Donofrio G; De La Barrera RA; Larocca RA; Zaky W; Mendez-Rivera L; Choe M; Davidson E; McCracken MK; Brien JD; Abbink P; Bai H; Bryan AL; Bias CH; Berry IM; Botero N; Cook T; Doria-Rose NA; Escuer AGI; Frimpong JA; Geretz A; Hernandez M; Hollidge BS; Jian N; Kabra K; Leggat DJ; Liu J; Pinto AK; Rutvisuttinunt W; Setliff I; Tran U; Townsley S; Doranz BJ; Rolland M; McDermott AB; Georgiev IS; Thomas R; Robb ML; Eckels KH; Barranco E; Koren M; Smith DR; Jarman RG; George SL; Stephenson KE; Barouch DH; Modjarrad K; Michael NL; Joyce MG; Krebs SJ
    Nat Med; 2020 Feb; 26(2):228-235. PubMed ID: 32015557
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dengue and Zika virus infections are enhanced by live attenuated dengue vaccine but not by recombinant DSV4 vaccine candidate in mouse models.
    Shukla R; Beesetti H; Brown JA; Ahuja R; Ramasamy V; Shanmugam RK; Poddar A; Batra G; Krammer F; Lim JK; Kale S; Lal AA; Swaminathan S; Khanna N
    EBioMedicine; 2020 Oct; 60():102991. PubMed ID: 32949997
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Maternally Acquired Zika Antibodies Enhance Dengue Disease Severity in Mice.
    Fowler AM; Tang WW; Young MP; Mamidi A; Viramontes KM; McCauley MD; Carlin AF; Schooley RT; Swanstrom J; Baric RS; Govero J; Diamond MS; Shresta S
    Cell Host Microbe; 2018 Nov; 24(5):743-750.e5. PubMed ID: 30439343
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Zika virus pathogenesis in rhesus macaques is unaffected by pre-existing immunity to dengue virus.
    Pantoja P; Pérez-Guzmán EX; Rodríguez IV; White LJ; González O; Serrano C; Giavedoni L; Hodara V; Cruz L; Arana T; Martínez MI; Hassert MA; Brien JD; Pinto AK; de Silva A; Sariol CA
    Nat Commun; 2017 Jun; 8():15674. PubMed ID: 28643775
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cross-Reactive Dengue Virus Antibodies Augment Zika Virus Infection of Human Placental Macrophages.
    Zimmerman MG; Quicke KM; O'Neal JT; Arora N; Machiah D; Priyamvada L; Kauffman RC; Register E; Adekunle O; Swieboda D; Johnson EL; Cordes S; Haddad L; Chakraborty R; Coyne CB; Wrammert J; Suthar MS
    Cell Host Microbe; 2018 Nov; 24(5):731-742.e6. PubMed ID: 30439342
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dengue and Zika Virus Domain III-Flagellin Fusion and Glycan-Masking E Antigen for Prime-Boost Immunization.
    Lin HH; Yang SP; Tsai MJ; Lin GC; Wu HC; Wu SC
    Theranostics; 2019; 9(16):4811-4826. PubMed ID: 31367259
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Zika convalescent macaques display delayed induction of anamnestic cross-neutralizing antibody responses after dengue infection.
    Valiant WG; Huang YS; Vanlandingham DL; Higgs S; Lewis MG; Mattapallil JJ
    Emerg Microbes Infect; 2018 Jul; 7(1):130. PubMed ID: 30006514
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dengue Virus and Zika Virus Serological Cross-reactivity and Their Impact on Pathogenesis in Mice.
    Watanabe S; Tan NWW; Chan KWK; Vasudevan SG
    J Infect Dis; 2019 Jan; 219(2):223-233. PubMed ID: 30085051
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of Envelope Protein Antigens To Serologically Differentiate Zika Virus Infection from Dengue Virus Infection.
    Premkumar L; Collins M; Graham S; Liou GA; Lopez CA; Jadi R; Balmaseda A; Brackbill JA; Dietze R; Camacho E; De Silva AD; Giuberti C; Dos Reis HL; Singh T; Heimsath H; Weiskopf D; Sette A; Osorio JE; Permar SR; Miley MJ; Lazear HM; Harris E; de Silva AM
    J Clin Microbiol; 2018 Mar; 56(3):. PubMed ID: 29263206
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pre-Existing Dengue Immunity Drives a DENV-Biased Plasmablast Response in ZIKV-Infected Patient.
    Bhaumik SK; Priyamvada L; Kauffman RC; Lai L; Natrajan MS; Cho A; Rouphael N; Suthar MS; Mulligan MJ; Wrammert J
    Viruses; 2018 Dec; 11(1):. PubMed ID: 30597938
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 62.